Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for Brainstorm’s proprietary NurOwn® (MSC-NTF cells) technology in territories including the U.S., E.U., Canada, Israel and Hong Kong.
The Congress Member Who Bought Shares Of Trump’s SPAC Probably Won’t Surprise You
A SPAC merger is bringing Donald Trump’s new social media platform and plans for media assets public. Many retail traders bought the stock since the deal was announced along with at least one member of the U.S. Congress.
